IN2015DN04209A - - Google Patents

Download PDF

Info

Publication number
IN2015DN04209A
IN2015DN04209A IN4209DEN2015A IN2015DN04209A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A IN 4209DEN2015 A IN4209DEN2015 A IN 4209DEN2015A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A
Authority
IN
India
Prior art keywords
methods
igf1r
cancers
insulin
constituent
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Jeffery Leedman
Keith Michael Giles
Rikki Ann Mary Brown
Original Assignee
Univ Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904570A external-priority patent/AU2012904570A0/en
Application filed by Univ Western Australia filed Critical Univ Western Australia
Publication of IN2015DN04209A publication Critical patent/IN2015DN04209A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
IN4209DEN2015 2012-10-18 2013-10-18 IN2015DN04209A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012904570A AU2012904570A0 (en) 2012-10-18 Cancer therapy using miRNAs
PCT/AU2013/001208 WO2014059484A1 (fr) 2012-10-18 2013-10-18 Thérapie anticancéreuse à l'aide de miarn

Publications (1)

Publication Number Publication Date
IN2015DN04209A true IN2015DN04209A (fr) 2015-10-16

Family

ID=50487345

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4209DEN2015 IN2015DN04209A (fr) 2012-10-18 2013-10-18

Country Status (5)

Country Link
US (1) US9795626B2 (fr)
EP (1) EP2908830A4 (fr)
CN (1) CN104994861B (fr)
IN (1) IN2015DN04209A (fr)
WO (1) WO2014059484A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800256A1 (fr) * 2012-11-06 2021-04-07 InteRNA Technologies B.V. Combinaison à utiliser dans le cadre d'un usage thérapeutique contre des maladies ou des affections associées au mélanome ou à l'activation de la voie de signalisation braf
ES2596711B1 (es) * 2015-07-09 2017-10-27 Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Paz Determinación de la metilación y niveles de un miARN en respuesta a un compuesto antitumoral basado en platino
CN106367419A (zh) * 2016-10-10 2017-02-01 徐州医科大学 具有神经保护作用的反义寡核苷酸、药物组合物及其应用
EP3571200B8 (fr) 2017-01-17 2022-08-03 HepaRegeniX GmbH Inhibiteurs de protéine kinase pour favoriser la régénération du foie, ou pour réduire ou prévenir la mort des hépatocytes
WO2018226802A1 (fr) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction de létalité synthétique à l'aide de la thérapie épigénétique
AU2018344761A1 (en) * 2017-10-03 2020-05-07 GeneSeq Pty Ltd A method of diagnosis, staging and monitoring of melanoma using microrna gene expression
CN109536497A (zh) * 2018-11-28 2019-03-29 同济大学 日本血吸虫感染及其组分在人类肿瘤预防和治疗中的应用
US11750706B1 (en) * 2020-03-26 2023-09-05 Amazon Technologies, Inc. Data transmission time management

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557411T3 (es) 2006-01-05 2016-01-25 The Ohio State University Research Foundation Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos
JP2013511559A (ja) * 2009-11-24 2013-04-04 ザ ユニバーシティ オブ ウェスタン オーストラリア 上皮成長因子受容体リガンドのモジュレーション

Also Published As

Publication number Publication date
WO2014059484A1 (fr) 2014-04-24
US20150366895A1 (en) 2015-12-24
EP2908830A1 (fr) 2015-08-26
CN104994861B (zh) 2019-10-11
US9795626B2 (en) 2017-10-24
EP2908830A4 (fr) 2016-11-30
CN104994861A (zh) 2015-10-21

Similar Documents

Publication Publication Date Title
IN2015DN04209A (fr)
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
PH12015500825A1 (en) Substituted benzene compounds
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2013011922A (es) Compuestos de benceno substituido.
GB201106743D0 (en) Novel compounds
IN2015DN02032A (fr)
MX2015007180A (es) Moduladores del receptor huerfano gamma relacionado con retinoide (ror-gamma) para usarse en el tratamiento de enfermedades autoinmunes inflamatorias.
MY185016A (en) Progenitor cells of mesodermal lineage
EP2558124A4 (fr) Compositions de polysaccharide et procédés d'utilisation pour le traitement et la prévention de troubles associés à la mobilisation de cellules progénitrices
MX2013004061A (es) Analogos de ciclosporina.
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
IN2015MN00027A (fr)
MX2013004062A (es) Analogos de ciclosporina.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2013008559A (es) Derivados de leptina.
GB201212586D0 (en) Cancer treatment